Investigates IL-1 alpha's role in drug resistance against EGFR inhibitors in head and neck cancer, suggesting a potential therapeutic target.
Key Points
This research aims to identify the role of IL-1α in drug resistance to various generations of EGFR inhibitors in head and neck squamous cell carcinoma.
HNSCC cell lines treated with first to fourth generation EGFR TKIs for 48 hours
Cell viability assessed using MTT assays
Cytokine expression measured by ELISA and Western blot
IL-1 signaling manipulated using neutralizing antibodies and receptor antagonists
All EGFR TKIs triggered IL-1α release in HNSCC cell lines
IL-6 release was also increased, dependent on IL-1α
Overexpression of IL-1α led to resistance against all EGFR TKIs
Erlotinib-resistant cells showed resistance to other EGFR inhibitors